Dr. Salim Dhanji reports

ME THERAPEUTICS HOLDINGS INC. ANNOUNCES GRANT OF STOCK OPTIONS

ME Therapeutics Holdings Inc. has granted 250,000 incentive stock options to purchase up to 250,000 common shares of the company to an arm's-length consultant of the company under its stock option plan. The options are exercisable for a period of three years from the date of grant, expiring on April 8, 2027, at a price of $3.51 per share, and vest as follows: (i) 25 per cent on the date of the grant; (ii) 50 per cent on the date that is six months after the date of grant; and (iii) 25 per cent on the date that is nine months after the date of grant.

All options and the shares underlying such options are subject to a hold period of four months and one day from the date of issuance.

About ME Therapeutics Holdings Inc.

ME Therapeutics (myeloid enhancement therapeutics) is an early-stage Vancouver-based biotechnology company involved in the discovery and development of novel immuno-oncology therapeutics targeting immune suppression in cancer. Its main focus is on overcoming the suppressive effects of an important class of immune cells called myeloid cells to enhance anti-cancer immunity.